15 Best Large-Cap Value Stocks to Buy in 2025

Page 8 of 14

7. AstraZeneca PLC (NASDAQ:AZN)

Analyst Upside as of January 20, 2025: 31%

Number of Hedge Fund Holders: 42

AstraZeneca PLC (NASDAQ:AZN) ranks seventh on our list of the best large-cap value stocks to buy in 2025. AstraZeneca is a pharmaceutical company headquartered in Cambridge, United Kingdom. In the third quarter of 2024, the company logged $39.18 billion in revenue, up by 19%. Of this, product revenue was $37.6 billion, accounting for most of the sales. For the fiscal year 2024, AstraZeneca PLC (NASDAQ:AZN) upgraded its revenue guidance to grow by a high-teen percentage.

AZN is positioned for long-term success, given it aims to make $80 billion in revenue by 2030 and register sustained growth ahead of 2030. The company expects to reach this parameter by launching at least 20 new medicines by 2030 and accelerating the processing of existing medicines. Beyond 2030, AstraZeneca PLC (NASDAQ:AZN) intends to invest in disruptive categories that will shape the future of healthcare such as cell therapy, gene therapy, and next-generation immunotherapy.

On January 20, Sachin Jain, an analyst from Bank of America Securities, reiterated a buy rating on the stock with a $91.70 price target. Jain gave a buy rating on the stock because AZN has displayed robust growth from key products. In addition to that, the analyst remains particularly optimistic about the company’s future growth potential and promising pipeline.

Page 8 of 14